Adverse Clinical Events Among Medicare Beneficiaries Using Antipsychotic Drugs

OBJECTIVE: Medicare Part D provides formulary protections for antipsychotics but does not exempt these drugs from cost-sharing. We investigated the impact of Part D coverage on antipsychotic drug spending, adherence, and clinical outcomes among beneficiaries with varying indications for use. METHODS: We conducted a historical cohort study of Medicare Advantage beneficiaries who received antipsychotic drugs, with diagnoses of schizophrenia or bipolar disorder or with no mental health diagnoses (N=10,190). Half had a coverage gap; half had no gap because of low-income subsidies. Using fixed effects regression models, we examined changes in spending and adherence as beneficiaries experienced cost-sharing increases after reaching the gap. We examined changes in hospitalizations and emergency department visits using proportional hazard models. RESULTS: Across all diagnostic groups, total monthly expenditure on antipsychotic drugs decreased with cost-sharing increases in the gap compared with those with no gap (eg, schizophrenia: -$123 95% confidence interval [-$138, -$108]), and out-of-pocket spending increased (eg, schizophrenia: $104 [$98, $110]). Adherence similarly decreased, with the largest declines among those with schizophrenia (-20.6 percentage points [-22.3, -18.9] in proportion of days covered). Among beneficiaries with schizophrenia and bipolar disorder, hospitalizations and emergency department visit rates increased with cost-sharing increases (eg, schizophrenia: hazard ratio=1.32 [1.06, 1.65] for all hospitalizations), but did not among subjects without mental health diagnoses. Clinical event rates did not change among beneficiaries with low-income subsidies without gaps. CONCLUSIONS: There is evidence of interruptions in antipsychotic use attributable to Part D cost-sharing. Adverse events increased among beneficiaries with approved indications for use, but not among beneficiaries without such indications

Antipsychotic · Bipolar disorder · Cognition · Confidence interval · Cost sharing · Emergency department · Family medicine · Formulary · Hazard ratio · Medical prescription · Medicare Part D · Mental health · Prescription drug · Psychiatry · Schizophrenia (object-oriented programming) · Emergency Medicine · Health Systems, Economic Evaluations, Quality of Life · Internal Medicine · Medication Adherence and Compliance · Medicine · Pharmaceutical Economics and Policy

• Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use

  Open Access•Vicki Fung, Mary Price et al.•JAMA Health Forum•2024

  Add to list

• Prescription Drug Insurance Coverage and Patient Health Outcomes

  Aaron S Kesselheim, Krista F Huybrechts et al.•American Journal of Public Health•2015

  Add to list

• The assessment of refill compliance using pharmacy records

  Open Access•J F Steiner, Allan V Prochazka•Journal of Clinical Epidemiology•1997

  Add to list

• Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission

  Marcia Valenstein, Laurel A Copeland et al.•Medical Care•2002

  Add to list

• Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness

  Christine Y Lu, Stephen B Soumerai et al.•Medical Care•2010

  Add to list